{% extends "layout.html" %}
  
{% block title %}Wet Lab{% endblock %}
{% block lead %}This serves as a chronological record of our team's wet lab experimental strategy, documenting our design logic, constructs, and planned validation workflows.{% endblock %}

{% block scroll_nav %}
<nav class="side-scroll-nav scroll-nav" style="font-size: 0.7rem; width: 180px;">
  <span class="side-scroll-nav-label">On This Page</span>
  <a href="#strain-engineering"><span class="highlight-green">Strain Engineering</span></a>
  <a href="#growth-factors"><span class="highlight-green">Production of Recombinant Growth Factors</span></a>
  <a href="#biokernel-validation"><span class="highlight-green">Downstream Characterisation</span></a>
  <a href="#references">References</span></a>
</nav>
{% endblock %}

{% block page_content %}
<!-- HERO BANNER -->
<div class="education-hero dsp-banner"
     style="background-image: url('https://static.igem.wiki/teams/5916/assets/wetlab-banner.avif');
            background-size: cover;
            background-position: center;
            background-repeat: no-repeat;
            width: 100%;
            height: 300px;
            display: flex;
            align-items: center;
            justify-content: flex-start;
            padding-left: 10%;
            color: white;
            text-align: left;">
  <div class="education-hero-content-container">
    <h1 class="text-glitch">WET LAB</h1>
  </div>
</div>

<div class="spacer5"></div>

<!-- EXPERIMENTAL DESIGN INTRO -->
<div class="page-section width-75" style="margin-left: 220px; margin-bottom: 3rem;" id="experimental-design">
  <h2 style="text-align: left;">
    <span class="animate-text-scramble">Experimental Design</span>
  </h2>

  <p style="text-align: left; margin-bottom: 1.5rem;">
    <strong>We conducted three key experiments for our overall proof of concept:</strong>
  </p>

  <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
    <li>The <strong>CRISPR/Cas9-based engineering of EPS-related pathways</strong> to minimise exopolysaccharide production and secretion.</li>
    <li>The production of <strong>recombinant growth factors from <em>K. phaffii</em></strong> for use in the cultivated meat industry.</li>
    <li><strong>Optimisation of an enzymatic pathway in <em>E. coli</em></strong> as validation for a no-code Bayesian optimisation workflow for future <em>K. phaffii</em> metabolic engineering and media optimisation.</li>
  </ul>

  <p style="text-align: left; margin-bottom: 1.5rem;">
    These experimental lines together span our integrated pipeline — from <strong>strain-level genetic engineering</strong> and
    <strong>recombinant protein production</strong> to <strong>automation and optimisation of bioprocesses</strong>.
  </p>
</div>
<!-- STRAIN ENGINEERING (dropdown) -->
<div class="page-section width-75" style="margin-left: 220px; margin-bottom: 3rem;" id="strain-engineering">
  <h2 style="text-align: left;">
    <span class="highlight-green animate-text-scramble">Strain Engineering K.phaffii</span>
  </h2>

  <details style="margin-top: 1rem; margin-bottom: 2rem;">
    <summary style="cursor: pointer; font-weight: bold;">Show Details</summary>
    <div style="margin-top: 1rem;">

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We spread our engineering strategy such that it addressed <strong>the most mechanistically plausible causes for EPS secretion</strong>,
        which to date have not been conclusively identified in literature.
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li>Our first theory was that the truncated <strong>Hoc1</strong> enzyme results in <strong>less glycan branching</strong> and consequently more free mannans in the extracellular space.</li>
        <li>Secondly, a <strong>cell wall stress response</strong> due to thinner cell walls may drive excess mannans into the Golgi apparatus.</li>
        <li>Finally, if neither mechanism proved true, we aimed to <strong>reduce intracellular mannose synthesis</strong> directly by downregulating its metabolic precursor pathways.</li>
      </ul>

      <h3 style="text-align: left; margin-top: 2rem;">Why We Target Exopolysaccharides</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Through both our integrated human practices with <strong>Magnify Bio</strong> and <strong>Liberation Bioindustries</strong> and a review of recent literature, we identified
        <strong>exopolysaccharides (EPS)</strong> as a critical impurity complicating downstream processing in <em>K. phaffii</em>-based production systems.
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li>EPS impurities <strong>co-migrate with recombinant proteins</strong> in size-based purification such as micro- or ultrafiltration, greatly complicating scalable separation<sup>[10–12]</sup>.</li>
        <li>They can <strong>agglomerate with proteins</strong> and form dense “cake” layers on membranes, leading to fouling and yield loss<sup>[12]</sup>.</li>
        <li>Even high-effort recovery methods like anion exchange <strong>fail when charge distributions overlap</strong><sup>[12]</sup>.</li>
        <li>These impurities are increasingly recognised as <strong>major cost drivers</strong> in scaling recombinant protein production<sup>[10]</sup>.</li>
        <li>Up to <strong>4% of cell dry weight</strong> may consist of these unwanted mannans<sup>[10,12]</sup>, representing both a yield and energy loss.</li>
      </ul>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        To our knowledge, <strong>no previous studies have addressed EPS secretion at the strain-engineering level</strong> — representing a significant opportunity to improve downstream efficiency for multiple protein products.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Accordingly, we decided on <strong>one genetic target per mechanistic hypothesis</strong>, resulting in three distinct modification strategies:
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li><strong>Hoc1</strong> — a 1,6-mannosyltransferase responsible for branching of glycan arms on glycoproteins.</li>
        <li><strong>PMI</strong> — phosphomannose isomerase, linking fructose-6-phosphate to mannose-6-phosphate (GDP-mannose synthesis).</li>
        <li><strong>Rho1</strong> — a GTPase in the cell wall integrity pathway, modulating wall biosynthesis and stress response.</li>
      </ul>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Because the <strong>Hoc1 truncation</strong> in industrial strains improves secretion and transformability, we avoided restoring full-length activity.
        Instead, we aimed to <strong>downregulate Hoc1</strong> to reduce EPS while retaining secretion performance.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We acknowledged potential trade-offs — such as tighter cell walls reducing secretion efficiency or altered central metabolism slowing growth —
        and therefore distributed our engineering targets across <strong>metabolic, structural, and regulatory layers</strong> for balanced impact.
      </p>

      <h3 style="text-align: left; margin-top: 2rem;">Engineering Approach</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        To modify <strong>Hoc1</strong> and <strong>PMI</strong>, we adopted the <strong>CRISPR/Cas9 system</strong> as a modular and well-characterised editing tool.
        However, given <strong>commercial patent constraints</strong> around CRISPR, we evaluated <strong>split-marker homologous recombination</strong> as a
        viable, license-free alternative that achieves the same edits through native yeast recombination mechanisms.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Following <strong>Gassler et al.</strong><sup>[1]</sup>, we designed <strong>ten sgRNA devices</strong> with flanking 5′ hammerhead (HH) and 3′ hepatitis delta virus (HDV)
        ribozymes for efficient self-excision and processing. Target regions were selected around the start and stop codons of
        <em>Hoc1</em> and <em>PMI</em> to minimise unintended modifications.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        For <strong>Rho1</strong>, we planned a mild overexpression under the weak constitutive promoter <strong>pPGK1</strong> to partially reinforce
        cell wall integrity without impairing cell proliferation<sup>[2]</sup>.
      </p>

      <p style="text-align: left;">
        By combining these strategies, our engineered strains aim to <strong>reduce EPS secretion at the source</strong>,
        improve recombinant protein yield, and maintain commercial feasibility by avoiding patent-encumbered technologies.
      </p>

    </div>
  </details>
</div>
<!-- RECOMBINANT GROWTH FACTORS (dropdown) -->
  <div class="page-section width-75" style="margin-left: 220px; margin-bottom: 3rem;" id="growth-factors">
  <h2 style="text-align: left;">
    <span class="highlight-green animate-text-scramble">Production of Recombinant Growth Factors</span>
  </h2>

  <details style="margin-top: 1rem; margin-bottom: 2rem;">
    <summary style="cursor: pointer; font-weight: bold;">Show Details</summary>
    <div style="margin-top: 1rem;">

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Our growth factor experiment planned to <strong>demonstrate the ability of <em>K. phaffii</em> to produce recombinant mammalian growth factors at high titres</strong>
        and to <strong>characterise the production of HGF and IGF-1 in <em>K. phaffii</em> for the first time in iGEM</strong>.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We chose to target <strong>four growth factors</strong> based on their roles in muscle growth and tissue regeneration:
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li><strong>Epidermal Growth Factor (EGF)</strong> — stimulates cell proliferation and differentiation<sup>[3]</sup>.</li>
        <li><strong>Basic Fibroblast Growth Factor (bFGF)</strong> — promotes strong proliferation and migration of myocytes<sup>[4]</sup>.</li>
        <li><strong>Hepatocyte Growth Factor (HGF)</strong> — activates muscle satellite cells and supports regeneration<sup>[5]</sup>.</li>
        <li><strong>Insulin-like Growth Factor 1 (IGF-1)</strong> — promotes cell proliferation in muscle and bone<sup>[6]</sup>.</li>
      </ul>

      <h3 style="text-align: left; margin-top: 2rem;">Secretion Strategy</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We engineered these growth factors to be secreted using a <strong>pre-Ost1–pro-α mating factor fusion secretion tag</strong>.
        Traditionally, <em>K. phaffii</em> relies on the full α-mating factor from <em>S. cerevisiae</em> to mediate protein secretion,
        but this sequence can <strong>slow translocation of large proteins</strong> such as FGF2 or HGF and may cause
        <strong>aggregation during high-volume expression</strong>.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Based on Barrero et al. (2018), we employed a <strong>hybrid signal</strong> consisting of the <em>pre-factor</em> of Ost1 fused to the <em>pro-region</em>
        of the α-mating factor, resulting in <strong>up to 20× higher secretion efficiency</strong> for some proteins<sup>[7]</sup>.
      </p>

      <h3 style="text-align: left; margin-top: 2rem;">Purification and Tagging</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        To facilitate purification, we appended a <strong>C-terminal poly-histidine (6×His) tag</strong> using a flexible <strong>G₄S×₃ linker</strong>.
        This design enables <strong>nickel spin column affinity chromatography</strong> for efficient recovery of growth factors.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        While His-tags are sometimes immunogenic, our rationale for using them was twofold:
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li>We do <strong>not intend therapeutic use</strong>, so minor immunogenicity poses no risk.</li>
        <li>His-tag purification is a <strong>low-cost, low-labour</strong> method ideal for lab-scale validation.</li>
      </ul>

      <p style="text-align: left;">
        Together, this secretion and purification design ensured our constructs would combine <strong>high yield</strong>,
        <strong>process scalability</strong>, and <strong>experimental practicality</strong>.
      </p>

      <h3 style="text-align: left; margin-top: 2rem;">Strain Map</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        The proposed experimental pathway resulted in several distinct <em>K. phaffii</em> strains for characterisation:
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li><strong>CRISPR transformants</strong> — strains with downregulated or repaired <em>Hoc1</em> and <em>PMI</em> genes.</li>
        <li><strong>Rho1-engineered constructs</strong> — co-expressing <em>Rho1</em> or <em>mCherry</em> (control) alongside growth factor plasmids.</li>
        <li><strong>Growth factor expression strains</strong> — producing EGF, bFGF, HGF, or IGF-1 under secretion and His-tag constructs.</li>
      </ul>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We prioritised <strong>bFGF</strong> for initial validation due to its previously characterised size and secretion profile,
        with <strong>HGF</strong> as a secondary focus if secretion proved feasible without additional chaperone expression.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        To verify biological activity, we planned to assess the <strong>proliferative potential of our recombinant growth factors</strong>
        in <strong>bovine muscle cells</strong>, comparing their effects against <strong>commercial FBS and recombinant standards</strong>
        (e.g., from <em>E. coli</em> or CHO systems). Unfortunately, this was not completed due to time limitations.
      </p>

      <div class="image-aligner-center" style="text-align: center; margin: 2rem 0;">
        <img src="https://static.igem.wiki/teams/5916/wetlab/wettypic1.avif"
             alt="Illustrative strain map of K. phaffii constructs"
             style="max-width: 50%; border-radius: 0.5rem;" class="tilt-effect">
      </div>

    </div>
  </details>
</div>
<!-- DOWNSTREAM CHARACTERISATION (dropdown) -->
<div class="page-section width-75" style="margin-left: 220px; margin-bottom: 3rem;" id="downstream-characterisation">
  <h2 style="text-align: left;">
    <span class="highlight-green animate-text-scramble">Downstream Characterisation</span>
  </h2>

  <details style="margin-top: 1rem; margin-bottom: 2rem;">
    <summary style="cursor: pointer; font-weight: bold;">Show Details</summary>
    <div style="margin-top: 1rem;">

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Following the production of recombinant growth factors in <em>K. phaffii</em>, we designed a downstream workflow to
        <strong>quantify and compare the production of both recombinant proteins (desired products) and exopolysaccharides (side products)</strong>
        across our engineered strains.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        Our goal was to correlate <strong>EPS reduction</strong> with <strong>improved protein purity and yield</strong> —
        providing measurable confirmation that our strain-level engineering translated to bioprocessing advantages.
      </p>

      <div class="image-aligner-center" style="text-align: center; margin: 2rem 0;">
        <img src="https://static.igem.wiki/teams/5916/wetlab/wettypic2.avif"
             alt="Overview of downstream characterisation workflow"
             style="max-width: 55%; border-radius: 0.5rem;" class="tilt-effect">
      </div>

      <h3 style="text-align: left; margin-top: 2rem;">EPS Quantification</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We developed a <strong>colorimetric dual-assay workflow</strong> to estimate the concentration of extracellular polysaccharides,
        most of which are mannans<sup>[11]</sup>. Our approach involved quantifying both total sugars and reducing sugars, where the
        <strong>difference between the two</strong> represents the polysaccharide fraction.
      </p>

      <ul style="text-align: left; padding-left: 1.5rem; margin-bottom: 1.5rem;">
        <li><strong>Phenol–Sulfuric Acid (PSA) Assay</strong><sup>[13]</sup> — quantifies total carbohydrate concentration by acid hydrolysis of all saccharides.</li>
        <li><strong>Dinitrosalicylic Acid (DNS) Assay</strong><sup>[14]</sup> — quantifies reducing sugars through a redox reaction with 3,5-dinitrosalicylic acid.</li>
      </ul>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        By running these assays in parallel, we could determine the approximate proportion of EPS within each supernatant sample,
        allowing comparison between engineered and control strains under identical conditions.
      </p>

      <h3 style="text-align: left; margin-top: 2rem;">Protein Purification and Quantification</h3>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        To isolate recombinant growth factors, we employed <strong>His-tag Ni–NTA affinity chromatography</strong>, leveraging the C-terminal 6×His tags
        fused to each construct via the G₄S(x3) flexible linker domain.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        We planned to use <strong>HisPur Ni–NTA resin (Thermo)</strong> to capture His-tagged proteins directly from the supernatant, followed by elution and quantification.
        Protein concentration was to be measured using the <strong>Bradford assay</strong>, enabling total growth factor quantification across samples.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        To ensure assay reliability, we planned to include controls using unmodified <em>K. phaffii</em> (PN-2 strain) cultures — both purified and unpurified —
        to identify background interference from native His-rich proteins.
      </p>

      <p style="text-align: left; margin-bottom: 1.5rem;">
        For advanced compositional analysis, we also prepared to send samples for <strong>HPLC characterisation</strong> to confirm the molecular weight and identity of produced proteins and polysaccharides.
        However, due to time constraints, this analysis was not completed during the project timeline.
      </p>

      <p style="text-align: left;">
        Despite limited experimental execution, this pipeline provides a <strong>complete validation framework</strong> for future teams:
        one that couples <strong>strain-level EPS mitigation</strong> with <strong>protein yield enhancement</strong> through direct quantification of both
        intended and unintended outputs in recombinant protein production.
      </p>

    </div>
  </details>
</div>
<!-- REFERENCES -->
<div class="page-section width-75" style="margin-left: 220px; margin-bottom: 3rem;" id="references">
  <h2 style="text-align: left;">
    <span class="animate-text-scramble">References</span>
  </h2>

  <ol style="text-align: left; padding-left: 1.5rem; line-height: 1.6;">

    <li>Gassler, T., Heistinger, L., Mattanovich, D., Gasser, B., & Prielhofer, R. (2019). 
      <em>CRISPR/Cas9-mediated homology-directed genome editing in <em>Pichia pastoris</em>.</em> 
      In Gasser & Mattanovich (Eds.), <em>Recombinant Protein Production in Yeast</em>, Methods in Molecular Biology, vol. 1923. 
      Humana Press. https://doi.org/10.1007/978-1-4939-9024-5_9
    </li>

    <li>Xu, S., Zhang, G.Y., Zhang, H., Kitajima, T., Nakanishi, H., & Gao, X.D. (2016). 
      <em>Effects of Rho1, a small GTPase, on the production of recombinant glycoproteins in <em>Saccharomyces cerevisiae</em>.</em> 
      <em>Microbial Cell Factories</em>, 15(1):179. https://doi.org/10.1186/s12934-016-0575-7
    </li>

    <li>Alexander, P., Yuan, L., & Yang, P. (2015). 
      <em>EGF promotes mammalian cell growth by suppressing cellular senescence.</em> 
      <em>Cell Research</em>, 25(1), 135–138. https://doi.org/10.1038/cr.2014.141
    </li>

    <li>Yun, Y.R., Won, J.E., Jeon, E., Lee, S., Kang, W., Jo, H., Jang, J.H., Shin, U.S., & Kim, H.W. (2010). 
      <em>Fibroblast growth factors: biology, function, and application for tissue regeneration.</em> 
      <em>Journal of Tissue Engineering</em>, 2010:218142. https://doi.org/10.4061/2010/218142
    </li>

    <li>Miller, K.J., Thaloor, D., Matteson, S., & Pavlath, G.K. (2000). 
      <em>Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle.</em> 
      <em>American Journal of Physiology–Cell Physiology</em>, 278(1):C174–C181. https://doi.org/10.1152/ajpcell.2000.278.1.C174
    </li>

    <li>Yoshida, T., & Delafontaine, P. (2020). 
      <em>Mechanisms of IGF-1–mediated regulation of skeletal muscle hypertrophy and atrophy.</em> 
      <em>Cells</em>, 9(9):1970. https://doi.org/10.3390/cells9091970
    </li>

    <li>Barrero, J.J., Casler, J.C., Valero, F., Ferrer, P., & Glick, B.S. (2018). 
      <em>An improved secretion signal enhances the secretion of model proteins from <em>Pichia pastoris</em>.</em> 
      <em>Microbial Cell Factories</em>, 17(1):161. https://doi.org/10.1186/s12934-018-1009-5
    </li>

    <li>Meyer, A.J., Segall-Shapiro, T.H., Glassey, E., Zhang, J., & Voigt, C.A. (2019). 
      <em>Escherichia coli “Marionette” strains with 12 highly optimized small-molecule sensors.</em> 
      <em>Nature Chemical Biology</em>, 15(2):196–204. https://doi.org/10.1038/s41589-018-0168-3
    </li>

    <li>Moore, S.J., Lai, H.E., Kelwick, R.J., Chee, S.M., Bell, D.J., Polizzi, K.M., & Freemont, P.S. (2016). 
      <em>EcoFlex: A multifunctional MoClo kit for <em>E. coli</em> synthetic biology.</em> 
      <em>ACS Synthetic Biology</em>, 5(10):1059–1069. https://doi.org/10.1021/acssynbio.6b00031
    </li>

  </ol>
</div>

{% endblock %}